Hyperbaric Oxygen Therapy Cancer: Impact on Tumor Growth

The best available evidence shows that hyperbaric oxygen therapy (HBOT) does not stimulate tumor growth or increase cancer recurrence. Multiple reviews spanning laboratory, animal, and clinical studies have reached this conclusion, and some research suggests HBOT may actually inhibit tumor progression in certain cancer types. The relationship between pressurized oxygen and cancer is more nuanced than a simple “helps or hurts” framing, though, particularly when HBOT is combined with conventional treatments like chemotherapy, radiation, or newer immunotherapies.

The Core Concern and What Reviews Actually Show

The worry that giving cancer patients extra oxygen might “feed” their tumors has been around for decades. The logic seems intuitive: tumors need oxygen to grow, so flooding the body with it could accelerate the disease. But the accumulated research points in the opposite direction. A comprehensive review in Targeted Oncology concluded there is no evidence that HBOT acts as a stimulator of tumor growth or an enhancer of recurrence, while noting evidence that it may have tumor-inhibitory effects in certain cancer subtypes.¹ An earlier review in Undersea and Hyperbaric Medicine reached a similar verdict: laboratory, animal, and clinical studies strongly suggest no more than a neutral effect on tumor growth, with some studies pointing toward a negative impact on malignant progression.²

A safety evaluation tracking cancer patients who received HBOT found that over a median follow-up of roughly two years, about 60% had no recurrence. Statistical analysis revealed no significant correlation between the number of HBOT sessions a patient received and either metastasis or mortality.³ No HBOT-related complications were observed during the treatment course in that study. This does not prove HBOT fights cancer on its own, but it does undercut the fear that it makes things worse.

Why Extra Oxygen Does Not Simply Feed Tumors

Tumors are paradoxically oxygen-starved environments. As a tumor grows, its blood supply becomes chaotic and disorganized, creating pockets of low oxygen called hypoxic zones. These zones are not a weakness for the tumor. They actually help it survive by activating molecular programs that promote new blood vessel formation, resistance to cell death, and the ability to spread. When HBOT substantially increases dissolved oxygen in plasma, it reoxygenates these hypoxic pockets and disrupts those survival programs rather than enhancing them.⁴

One of the key molecular targets is a protein called HIF-1α, which tumors rely on heavily in low-oxygen conditions. HIF-1α drives a cascade of changes that help cancer cells switch to less efficient energy pathways and become more aggressive. In non-small cell lung cancer cells, HBOT suppressed the expression of HIF-1α and its downstream signaling, interfering with the tumor’s metabolic adaptations to hypoxia.⁵ In plain terms, when oxygen levels rise, the tumor loses one of its main tools for thriving in a hostile environment.

How HBOT Can Trigger Tumor Cell Death

Beyond simply cutting off a survival pathway, high-pressure oxygen actively damages cancer cells through a mechanism involving reactive oxygen species, or ROS. These are chemically aggressive molecules that, in excess, overwhelm a cell’s defenses and trigger programmed cell death. In a lung cancer mouse model, animals treated with HBOT at 2.5 atmospheres for 90 minutes daily showed clear signs of tumor cell death after two weeks, confirmed by markers of a cellular self-destruct process called apoptosis. The researchers traced the effect to a buildup of hydrogen peroxide and superoxide inside tumor cells.⁶

This ROS-driven damage appears to be a consistent finding across multiple tumor types. A review of HBOT’s effects on the tumor microenvironment highlighted that the therapy regulates the tumor environment through several overlapping pathways: improving oxygen levels, targeting hypoxia-related signaling, and generating reactive oxygen species.⁷ The important nuance is that healthy cells typically handle oxidative stress better than cancer cells do. Tumors operating near the edge of metabolic survival are more vulnerable to the extra oxidative load.

Breast Cancer Models Show Direct Growth Suppression

Some of the most compelling animal data on direct tumor inhibition comes from breast cancer research. In a study using human breast cancer cells transplanted into mice, HBOT significantly suppressed tumor growth in both triple-positive and triple-negative subtypes. Both cell lines showed decreased proliferation after treatment.⁸ Triple-negative breast cancer is considered one of the most aggressive and treatment-resistant forms of the disease, so seeing growth suppression in that subtype is particularly interesting.

Separately, research targeting cancer stem cells, a small subpopulation within tumors thought to drive relapse and metastasis, found that HBOT directly inhibited these cells in both triple-negative breast cancer and pancreatic cancer mouse models. The oxygen therapy overcame tumor hypoxia and suppressed cancer stem cells both in culture dishes and in living animals, also reducing metastasis.⁹ This matters because even when a primary tumor responds to treatment, leftover cancer stem cells can seed new tumors elsewhere in the body.

Glioblastoma and the Case Where Oxygen Alone Is Not Enough

The picture gets more complicated with glioblastoma, the most aggressive primary brain cancer. This is where the research produces a genuinely mixed signal, and anyone reading about HBOT and cancer should understand the distinction.

One study found that in mouse models of glioblastoma, HBO exposure without chemotherapy actually increased tumor volume and shortened survival time. MRI showed larger tumors in HBO-treated mice compared to controls, and markers of cell proliferation were elevated. However, when the same experiment included the standard chemotherapy drug temozolomide, the HBO-exposed mice had smaller tumors and lived longer than mice receiving temozolomide alone. The median survival jumped from about 30.5 days to roughly 37 days in the HBO-plus-chemo group.¹⁰ The researchers concluded that while oxygen alone could accelerate glioblastoma growth, it simultaneously made the cancer cells more sensitive to chemotherapy by suppressing HIF pathways and stemness-related gene expression.

This finding aligns with earlier clinical data. A trial at Columbia-Preston Medical Center assigned 80 glioblastoma patients to either radiotherapy under hyperbaric oxygen or radiotherapy in normal air. After 18 months, survival was 28% in the oxygen group compared to 10% in the control group. By 36 months, no patients in the control group were alive, but two patients in the oxygen group survived beyond 45 months. In a separate study, patients who received radiotherapy within 15 minutes of HBO decompression showed tumor reduction of 50% or more in 73% of cases, compared to just 29% in the group that did not receive HBOT.¹¹

The takeaway for glioblastoma is not that HBOT is dangerous but that it appears to function as a treatment enhancer rather than a standalone therapy. A scoping review confirmed that when HBOT was combined with chemotherapy, tumor proliferation was significantly lower, and tumor size, weight, and growth were all inhibited. The researchers also found that up to half of hypoxic regions were reoxygenated after treatment.¹²

Enhancing Immunotherapy With Pressurized Oxygen

One of the more promising research directions involves pairing HBOT with immune checkpoint inhibitors, the class of drugs that help the immune system recognize and attack tumors. The problem with these drugs in solid tumors is twofold: the dense, fibrous tissue surrounding the tumor physically blocks immune cells and antibodies from getting in, and the low-oxygen environment inside the tumor suppresses the immune cells that do manage to infiltrate.

A study published in Advanced Science demonstrated that HBOT addressed both problems. The pressurized oxygen depleted the main structural components of the tumor’s protective matrix, making the tissue more penetrable. It also disrupted the hypoxia-driven immune suppression within the tumor. When combined with a PD-1 antibody, HBOT promoted delivery of the drug and infiltration of immune cells into the tumor interior, triggering a robust immune response and long-lasting immune memory that inhibited tumor relapses across various stroma-rich solid tumor types.¹³ The structural remodeling effect is worth emphasizing because one of the biggest challenges in immunotherapy is not that the drugs do not work, but that they cannot physically reach enough of the tumor to work effectively.

Combination With Chemotherapy and Nanomedicine

The synergy between HBOT and conventional chemotherapy extends beyond glioblastoma. In bladder cancer models, combining HBO with a mitochondria-targeting molecule called IR-780 significantly enhanced the anti-tumor effect. The oxygen therapy promoted cancer cell uptake of the drug and triggered excessive production of reactive oxygen species within the cells’ mitochondria, suppressing tumor growth and recurrence in animal models without apparent toxicity.¹⁴

Researchers are also exploring HBOT alongside newer biomedical engineering technologies. One line of work pairs the improved oxygenation from HBOT with targeted nanoparticle drug delivery, photosensitizers for light-based therapy, and even gene-editing tools. The rationale is that a less hypoxic, more permeable tumor environment allows these technologies to reach their targets more effectively.¹⁵ This is still early-stage work, but it illustrates how HBOT is increasingly being studied not as a cancer treatment in itself but as something that makes the tumor microenvironment more vulnerable to other therapies.

What Happens to Cancer Stem Cells

Cancer stem cells represent a small but stubborn fraction of tumor cells that can self-renew, resist conventional treatment, and drive both relapse and spread to distant organs. These cells thrive in hypoxic niches within tumors, which is one reason standard therapies often fail to eliminate them completely.

In orthotopic glioma models, where tumors are grown in the brain to mimic real disease conditions, HBOT suppressed markers associated with stemness. The proportion of cells expressing stem cell surface markers dropped significantly after HBO treatment, and expression of genes tied to stem cell maintenance was reduced.¹⁶ The beta-catenin pathway, which plays complex roles in both normal development and cancer, was upregulated, which introduces some uncertainty about the full downstream effects. But the overall pattern of stem cell suppression was consistent with findings in breast and pancreatic cancer models.

If this line of research holds up in human trials, it could address one of oncology’s most persistent frustrations: shrinking a tumor only to have it return because the stem cell population survived.

Practical Realities and Unanswered Questions

Despite the encouraging laboratory and animal data, HBOT is not currently a standard cancer treatment. Most of the evidence comes from preclinical models, which means the findings showed effects in cell cultures and mice. The clinical trials that do exist are small, and many of the most promising combination strategies have not yet been tested in large, randomized human studies.

There are also open questions about optimal protocols. The glioblastoma research highlights that timing matters: radiotherapy delivered within 15 minutes of HBO decompression was far more effective than radiotherapy delivered 30 minutes later.¹¹ Pressure levels, session duration, and frequency of treatment all vary across studies, and no consensus protocol has emerged for any specific cancer type.

For patients who are currently receiving HBOT for non-cancer conditions, such as wound healing, radiation injury, or decompression sickness, the existing evidence should be reassuring: the data does not support the fear that these treatments will promote tumor growth. For patients with active cancer who are curious about HBOT as a complement to their treatment, the research is genuinely promising but not yet mature enough to guide clinical decisions outside of a trial setting. The strongest evidence so far is that HBOT functions as a sensitizer, making tumors more responsive to chemotherapy, radiation, and immunotherapy, rather than acting as a standalone anti-cancer therapy. Whether that sensitizing effect translates into meaningful survival gains across different cancer types remains the central question that larger human trials need to answer.